Prolong Adjuvant Aromatase Inhibitor Therapy in Breast Cancer?

Video

Cancer Network spoke with Richard Gray, MSc, about the effects of prolonging adjuvant aromatase inhibitor therapy has on breast cancer patients.

Cancer Network spoke with Richard Gray, MSc, about the effects of prolonging adjuvant aromatase inhibitor therapy has on breast cancer patients.

Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Related Content